Targeting Advanced Prostate Cancer with STEAP1 Chimeric Antigen Receptor T Cell and Tumor-Localized IL-12 Immunotherapy

The authors reported broad expression of STEAP1 relative to prostate-specific membrane antigen in lethal metastatic prostate cancers and the development of a STEAP1-directed chimeric antigen receptor T cell therapy.